Corbus Pharmaceuticals Announces Pricing of Public Offering
NORWOOD, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (Nasdaq:CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today announced the pricing of an underwritten public offering of 4,325,000 shares of its common stock at a public offering price of $19.00 per share, for a total public offering size of approximately $82.2 million, before deducting underwriting discounts and estimated offering expenses. In addition, Corbus has granted the underwriters a 30-day option to purchase up to an additional 648,750 shares of its common stock on the same terms and conditions. All of the securities in the offering are being sold by Corbus. The offering is expected to close on or about February 2, 2024, subject to customary closing conditions.
Related news for (CRBP)
- Corbus Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
- Corbus Pharmaceuticals Announces Closing of $94.5 Million Public Offering of Common Stock including Full Exercise of Underwriters’ Option to Purchase Additional Shares
- Corbus Pharmaceuticals Announces Proposed Public Offering
- CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting Antibody Drug Conjugate Demonstrates Encouraging Safety and Efficacy in Patients with Nectin-4 Positive Tumors in First-In-Human Study Presented at ASCO-GU 2024